NNNN vs OCS: fair value comparison
Anbio Biotechnology and Oculis Holding AG · Updated 2026-10-19
NNNN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. OCS reports in CHF, so no same-currency fair-value verdict is published for it. Within Healthcare, NNNN currently ranks higher by quality score.
| NNNN | OCS | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $3.13 | $8.76 |
| 12-month range | $3.13–$41.11 | $7.17–$32.65 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #255 of 301 Healthcare | #257 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | — | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: NNNN fair value analysis · OCS fair value analysis